Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bowel perforation associated with intraperitoneal chromic phosphate instillation.

J Proctor1, D Doering, D Barnhill

  • 1Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, DC 20307.

Gynecologic Oncology
|January 1, 1990
PubMed
Summary

Intraperitoneal chromic phosphate is used for ovarian cancer. Delayed bowel injury, like colon perforation, is a rare complication that can occur months after treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chicago Medical Society, Meeting of Jan. 20.

The Chicago medical journal and examiner·2023
Same author

Chicago Medical Society: Meeting of March 17.

The Chicago medical journal and examiner·2023
Same author

Chicago Medical Society: Meeting of March 3.

The Chicago medical journal and examiner·2023
Same author

Cook County Hospital: Service of Dr. H. A. Johnson.

The Chicago medical journal and examiner·2023
Same author

Chicago Medical Society.

The Chicago medical journal and examiner·2023
Same author

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC.

The European physical journal. C, Particles and fields·2022

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Intraperitoneal chromic phosphate (32P) is a common adjuvant therapy for early-stage ovarian epithelial carcinoma.
  • Delayed bowel injury is a known, though infrequent, complication associated with 32P administration.

Observation:

  • This case report details a patient who developed colon perforation.
  • The perforation occurred four months after receiving intraperitoneal chromic phosphate treatment.

Findings:

  • The patient had stage IB ovarian papillary serous cystadenocarcinoma.
  • The colon perforation presented as a delayed complication following 32P therapy.

Implications:

  • Highlights the importance of monitoring for delayed gastrointestinal complications after intraperitoneal 32P treatment.

Related Experiment Videos

  • Suggests a need for further investigation into the mechanisms and risk factors for delayed bowel injury.
  • Informs clinical practice regarding long-term surveillance in ovarian cancer patients treated with 32P.